I am a pancreas cancer clinical investigator @MSKCancerCenter. Trained at @columbiacancer.
Joined April 2024
- Tweets 70
- Following 137
- Followers 244
- Likes 715
26 Photos and videos
Michael May retweeted
Jun 5
Thanks for tracking @Larvol !
Top trending GI cancer oncologists on đť•Ź during @ASCO 2026.
Ranked by views of oncologist posts on clinical trials.
Explore more insights and conference data from #ASCO26 👉 clin.larvol.com/conference/a…
#LARVOL #ASCO2026 #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #ClinicalOncology #GICancer #GastrointestinalCancer #GICSM #ColorectalCancer #GastricCancer #LiverCancer #PancreaticCancer | @marklewismd | @Erman_Akkus | @GIMedOnc | @ronanhsieh | @GillSharlene | @DaisukeKotani | @coffman_kelley | @DraMartinezLago | @ryanhuey | @ArndtVogel
1
12
1,845
Michael May retweeted
A key message from this #ASCO26 discussion: the U.S. remains at the forefront of oncology clinical trials, but increasing global competition is a call for improvement. We are committed to helping, but meaningful progress will require engagement from all stakeholders.
ALT Panelists take Q&A from the audience at the #ASCO26 annual meeting.
3
7
20
3,314
Jun 1
Practice changing EMERALD-3 trial: STRIDE improved PFS from 8.1 to 12.9 months in patients with HCC treated with TACE. Lenvatinib appears to add no additional benefit with added toxicity. @GABOUALFA @MSKCancerCenter @MSK_DeptOfMed
1
11
19
2,035
Michael May retweeted
⚠️ New findings presented in the plenary session at #ASCO26 suggest daraxonrasib could help usher in a new era of treatment for metastatic pancreatic cancer.
In a phase 3 study led by @EileenMOReilly and colleagues, patients receiving #daraxonrasib lived a median of 13.2 months compared with 6.7 months for those treated with chemotherapy.
"To date in my career, I have not seen this level of benefit from any single anti-cancer drug in this disease."
Learn more: bit.ly/435pwKo
5
32
99
6,656
May 31
So lucky to have @EileenMOReilly as a mentor. She is an extraordinary physician and is leading PDAC drug development into this new and exciting era. @MSKCancerCenter @MSK_DeptOfMed
May 31
Congratulations @EileenMOReilly @MSKCancerCenter @MSK_DeptOfMed Brian Wolpin Ziv Wainberg and all colleagues on a long awaited and badly needed game changer in #pancreascancer
7
54
3,248
May 31
Three first line metastatic KRAS inhibitor trials open at @MSKCancerCenter in the next few weeks. Many more here and coming soon in almost every disease setting. @CpcrMsk @EileenMOReilly @CentralParkWMD @AnupriyaSingha9
1
8
26
2,976
May 31
Daraxonrasib appears to work well regardless of type or presence of KRAS mutation, but more data will be very useful in smaller subgroups (KRAS WT).
6
24
1,417
May 31
Emotional standing ovation at the daraxonrasib plenary session.
1
6
44
1,408
Michael May retweeted
A clean sweep by GI ONC fellows on 2026 YIAs. Honored to work side by side with these investigators. It takes a village to raise talent, and we are all in.
The culture of excellence & resilience starts at the top with our Chair of Medicine and future ASCO President, Deb Schrag.
1
7
64
2,922
Michael May retweeted
A few butterflies🦋 before the #ASCO26 Plenary. #2025Plenary podium was unforgettable , but this seat is definitely more relaxed. Emotions are high for the PDAC and sarcoma presentations. If we can change practice in these recalcitrant diseases, anything is possible! 💜💜💜
1
14
156
6,585
Michael May retweeted
Historical day for patients with #PDAC. Hope this is just the cornerstone for RAS revolution. Congrats on leading physician scientists involved in this global effort, @EileenMOReilly for leading it, and happy that Italy is part of this, including my 🇮🇹 mentor @FilippoPietran4
Presented at #ASCO26:
Among patients with previously treated metastatic pancreatic ductal adenocarcinoma, the RAS(ON) inhibitor daraxonrasib led to significantly longer overall survival and progression-free survival than chemotherapy. Full phase 3 RASolute 302 trial results: nej.md/4nWaxvM
@ASCO
ALT Graph from a study published in the New England Journal of Medicine on daraxonrasib versus chemotherapy for metastatic pancreatic cancer. The x-axis represents months, and the y-axis shows the percentage of patients alive. Two lines indicate survival rates: daraxonrasib (blue) and chemotherapy (gray). The bottom section lists patients at risk over time. Title and journal logo are included.
1
4
12
567
May 31
2
8
52
5,084
Michael May retweeted
May 31
The overall survival curves for Daraxonrasib in 2nd line advanced #PancreaticCancer leave no doubt how impactful this advance is for the field & for patients. Congratulations Brian Wolpin, @EileenMOReilly & @md_oberstein et al.
A seminal #ASCO26 plenary!
nejm.org/doi/full/10.1056/NE…
2
64
200
14,292
May 31
Not sure if you can drive a truck between these curves, but definitely a large SUV.
Presented at #ASCO26:
Among patients with previously treated metastatic pancreatic ductal adenocarcinoma, the RAS(ON) inhibitor daraxonrasib led to significantly longer overall survival and progression-free survival than chemotherapy. Full phase 3 RASolute 302 trial results: nej.md/4nWaxvM
@ASCO
ALT Graph from a study published in the New England Journal of Medicine on daraxonrasib versus chemotherapy for metastatic pancreatic cancer. The x-axis represents months, and the y-axis shows the percentage of patients alive. Two lines indicate survival rates: daraxonrasib (blue) and chemotherapy (gray). The bottom section lists patients at risk over time. Title and journal logo are included.
3
4
75
7,404
May 31
Awesome oral presentation by Emily Alouani on MSH3 LOF as a potential independent predictor of immunotherapy benefit in pMMR/MSS cancers. @StadlerZsofia @MSKCancerCenter @MSK_DeptOfMed @ASCO
3
8
1,311
Michael May retweeted
Thrilled and honored on behalf of the whole team, patients, scientific community and more- congratulations and good luck to @BrianWolpin this afternoon @MSKCancerCenter @DanaFarber @RevMedicines - next step is translate to practice!
Remarkable results for patients with pancreatic cancer now published in @NEJM - congrats to @EileenMOReilly @DrShubhamPant @MiteshBorad and co-authors for leading one of the most transformative trials in this disease. @RevMedicines @ASCO #ASCO26
nejm.org/doi/full/10.1056/NE…
10
40
189
21,622
Michael May retweeted
MSK gastrointestinal medical oncologist @EileenMOReilly presented to a packed room at #ASCO26 today, discussing new findings and the growing momentum behind #RAS-targeted therapies in #pancreaticcancer.
1
15
29
1,944
Michael May retweeted
May 30
@ASCO
please
Let’s go back to including the trial conclusions only at the END of the presentations!
4
2
44
3,295
May 30
The RAS Frontier! Big changes coming to pancreas cancer shortly… @EileenMOReilly @MSKCancerCenter @MSK_DeptOfMed @CpcrMsk
1
6
28
2,853